SI0778023T1 - Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. - Google Patents

Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease.

Info

Publication number
SI0778023T1
SI0778023T1 SI9630586T SI9630586T SI0778023T1 SI 0778023 T1 SI0778023 T1 SI 0778023T1 SI 9630586 T SI9630586 T SI 9630586T SI 9630586 T SI9630586 T SI 9630586T SI 0778023 T1 SI0778023 T1 SI 0778023T1
Authority
SI
Slovenia
Prior art keywords
rapamycin
huntington
epilepsy
disease
treatment
Prior art date
Application number
SI9630586T
Other languages
English (en)
Slovenian (sl)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of SI0778023T1 publication Critical patent/SI0778023T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9630586T 1995-12-07 1996-12-04 Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. SI0778023T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07
EP96308786A EP0778023B1 (de) 1995-12-07 1996-12-04 Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington.

Publications (1)

Publication Number Publication Date
SI0778023T1 true SI0778023T1 (en) 2003-08-31

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630586T SI0778023T1 (en) 1995-12-07 1996-12-04 Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease.

Country Status (23)

Country Link
EP (1) EP0778023B1 (de)
JP (1) JPH09183727A (de)
KR (1) KR970032856A (de)
CN (1) CN1112925C (de)
AR (1) AR008747A1 (de)
AT (1) ATE234095T1 (de)
AU (1) AU700653B2 (de)
BR (1) BR9605895A (de)
CA (1) CA2192298A1 (de)
CZ (2) CZ354496A3 (de)
DE (1) DE69626610T2 (de)
DK (1) DK0778023T3 (de)
ES (1) ES2188730T3 (de)
HU (1) HUP9603370A3 (de)
IL (1) IL119778A (de)
MX (1) MX9606131A (de)
NO (1) NO309966B1 (de)
NZ (1) NZ299888A (de)
PT (1) PT778023E (de)
SI (1) SI0778023T1 (de)
SK (1) SK154796A3 (de)
TW (1) TW427904B (de)
ZA (1) ZA9610245B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (de) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
CN1802161A (zh) * 2003-04-09 2006-07-12 惠氏公司 [2－(8,9－二氧代－2,6－二氮杂双环[5.2.0]壬－1(7)－烯－2－基)烷基]－膦酸及其衍生物的鼻内给药药用组合物及用法
US7253153B2 (en) 2003-04-09 2007-08-07 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
ATE549342T1 (de) * 2004-12-20 2012-03-15 Wyeth Llc Rapamycinanaloge und deren verwendungen bei der behandlung proliferativer, entzündlicher und neurologischer störungen
EP1828203A2 (de) 2004-12-20 2007-09-05 Wyeth Rapamycinderivate und ihre verwendung bei der behandlung von nervenerkrankungen
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
EP2135607A1 (de) 2008-06-18 2009-12-23 Pharnext Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen
ES2685947T3 (es) * 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
EP2263665A1 (de) * 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2456437A4 (de) * 2009-07-24 2013-01-09 Inst Nat Rech Scient Kombinationen aus curcumoiden- und mtor-hemmern für die behandlung von tauopathien
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
JP6300906B2 (ja) 2013-06-05 2018-03-28 ファーネクストＰｈａｒｎｅｘｔ 併用医薬有効成分（ａｐｉ）用安定性経口液剤
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US20200354445A1 (en) * 2017-11-15 2020-11-12 Vanderbilt University Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
DE69626610D1 (de) 2003-04-17
ES2188730T3 (es) 2003-07-01
CA2192298A1 (en) 1997-06-08
CN1159915A (zh) 1997-09-24
AU7417896A (en) 1997-06-12
CZ6498A3 (cs) 1998-06-17
ATE234095T1 (de) 2003-03-15
IL119778A (en) 1999-07-14
KR970032856A (ko) 1997-07-22
PT778023E (pt) 2003-06-30
TW427904B (en) 2001-04-01
DE69626610T2 (de) 2003-10-02
HUP9603370A2 (en) 1997-05-28
NO965238D0 (no) 1996-12-06
AR008747A1 (es) 2000-02-23
HUP9603370A3 (en) 1998-12-28
BR9605895A (pt) 1998-08-18
IL119778A0 (en) 1997-03-18
CN1112925C (zh) 2003-07-02
EP0778023A1 (de) 1997-06-11
MX9606131A (es) 1997-08-30
EP0778023B1 (de) 2003-03-12
CZ354496A3 (cs) 1998-03-18
NO965238L (no) 1997-06-09
HU9603370D0 (en) 1997-01-28
JPH09183727A (ja) 1997-07-15
NO309966B1 (no) 2001-04-30
AU700653B2 (en) 1999-01-14
ZA9610245B (en) 1998-06-05
DK0778023T3 (da) 2003-06-30
SK154796A3 (en) 1997-09-10
NZ299888A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
SI0778023T1 (en) Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease.
EP1029540A3 (de) Verwendung von Droloxifen zur Behandlung von cardiovaskulären Erkrankungen
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AU7060896A (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
AU3560495A (en) Medicament inhaler
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
AU5215998A (en) Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
AU5801996A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
IL119417A0 (en) Drug for Parkinson's disease
AU5229496A (en) Substituted benzyloxycarbonylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
ZA966313B (en) Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents, and medicaments comprising them.
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
HUP9901376A3 (en) 1-methylcarbapenem derivatives, their use, production thereof and medicaments containing the same
ZA968091B (en) Substituted benzolyguanidines a process for their preparation their use as a medicament or diagnostic agent and medicament comprising them
AU2364597A (en) Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
EP0791358A4 (de) Medikament gegen ophthalmische erkrankungen
HUP9600665A2 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
HK1009938A1 (en) Product comprising rapamycin or particular derivatives and an nmda or ampa antagonist for use for the treatment of epilepsy or huntington's disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or huntington's disease
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
ZA944281B (en) Use of efaroxan and its derivatives for the preparation of a medicinal product intented for the treatment of parkinson's disease
AU2683595A (en) Amide compound, process for producing the same, and insecticidal/miticidal drug
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye